Patients w/ additional osteoporosis risk factors eg, chronic alcohol abuse, smokers, long-term therapy w/ drugs reducing bone mineral density eg, anticonvulsants or corticoids, family history of osteoporosis, malnutrition. Previously unknown gonadotroph cell pituitary adenoma; QT prolongation. Closely monitor patients w/ known depression during therapy. Patients suffering from vertebral metastasis, at risk of spinal cord compression, w/ urinary tract obstruction. Increased risk of bone loss & fracture, metabolic changes or CV diseases. Constant hypogonadotrophin amenorrhea. Periodically check blood testosterone & measure plasma oestradiol levels. Concomitant use w/ drugs that modify pituitary gonadotropin secretion & drugs prolonging QT interval. May affect ability to drive & use machines. Not to be used during pregnancy & lactation. Childn w/ progressive brain tumours. Mild to moderate vag bleeding, pseudo- & gonadotrophin-independent precocious puberty, slipped capital femoral epiphysis. Not to be given in girls >12 yr & boys 13-14 yr w/ bone maturation. 3.75 mg: Measure oestradiol & FSH prior to & every 3 mth during therapy. Increased risk of musculoskeletal disorders eg, joint or musculoskeletal pain. Regularly monitor CV risk factors, BP & blood glucose levels. 11.25 mg: Not indicated in transient precocious puberty & premature thelarche, pubarche & menarche.